Eugenio Fernandez

Eugenio Fernandez

Auto-generated profile, based on publicly available information

Eugenio Fernandez

Service d’oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Cell
Verified
Journal Article
Closed access
ARAntoni Ribas
Antoni Ribas
RDReinhard Dummer
Reinhard Dummer
IPIgor Puzanov
Igor Puzanov
AVAri VanderWalde
Ari VanderWalde
RARobert H.I. Andtbacka
Robert H.I. Andtbacka
GLGeorgina Venetia Long
Georgina Venetia Long

4 November 2015 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
GLGeorgina V Long
Georgina V Long
RDReinhard Dummer
Reinhard Dummer
ARAntoni Ribas
Antoni Ribas
IPIgor Puzanov
Igor Puzanov
OMOlivier Michielin
Olivier Michielin
FHF Stephen Hodi
F Stephen Hodi

1 May 2018 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
JJJaafar Jaafar
Jaafar Jaafar
EFEugenio Fernandez
Eugenio Fernandez
HAHeba Alwan
Heba Alwan
JPJacques Philippe
Jacques Philippe
Background Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy. However, their use is complicated by immune-related adverse events (irAEs), including endocrine adverse events (eAEs). Purpose We review the incidence, time to onset and resolution rate of dysthyroidism induced by PD-1/PD-L1 Ab, and the clinical, biological and radiological findings. We aim to discuss the potential mechanisms of PD-1/PD-L1 Ab-induced dysthyroidism, and to propose a management algorithm. Methods We performed a literature search of available clinical trials regarding PD-1/PD-L1 Ab in the PubMed database. We selected all English language clinical trials that included at least 100 patients. We also present selected case series or reports, retrospective studies and reviews related to this issue. Findings In patients treated with PD-1 Ab, hypothyroidism occurred in 2–10.1% and hyperthyroidism occurred in 0.9–7.8%. When thyroiditis was reported separately, it occurred in 0.34–2.6%. Higher rates were reported when PD-1 Ab were associated with other ICI or chemotherapy. The median time to onset of hyperthyroidism and hypothyroidism after PD-1 Ab initiation was 23–45 days and 2–3.5 months, respectively. Regarding PD-L1 Ab, hypothyroidism occurred in 0–10% and hyperthyroidism in 0.5–2% of treated patients. The average time to onset of dysthyroidism after PD-L1 Ab was variable and ranged from 1 day after treatment initiation to 31 months. Conclusion Dysthyroidism occurs in up to 10% of patients treated with PD-1/PD-L1 Ab. Hypothyroidism and reversible destructive thyroiditis are the most frequent endocrine adverse events (eAE) in PD-1/PD-L1 treated patients. Immune and non-immune mechanisms are potentially involved, independently of the presence of thyroid antibodies.

1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RVRémi VERNET
Rémi VERNET
EFEugenio Fernandez
Eugenio Fernandez
DMDenis Migliorini
Denis Migliorini
VAVirginie Ancrenaz
Virginie Ancrenaz
ECEmily Charrier
Emily Charrier
NMnicolas Mach
nicolas Mach
Over two decades, most cancer vaccines failed clinical development. Key factors may be the lack of efficient priming with tumor-specific antigens and strong immunostimulatory signals. MVX-ONCO-1, a personalized cell-based cancer immunotherapy, addresses these critical steps utilizing clinical-grade material to replicate a successful combination seen in experimental models: inactivated patient’s own tumor cells, providing the widest cancer-specific antigen repertoire and a standardized, sustained, local delivery over days of a potent adjuvant achieved by encapsulated cell technology. We conducted an open-label, single-arm, first-in-human phase I study with MVX-ONCO-1 in patients with advanced refractory solid cancer. MVX-ONCO-1 comprises irradiated autologous tumor cells coimplanted with two macrocapsules containing genetically engineered cells producing granulocyte–macrophage colony-stimulating factor. Patients received six immunizations over 9 weeks without maintenance therapy. Primary objectives were safety, tolerability, and feasibility, whereas secondary objectives focused on efficacy and immune monitoring. Data from 34 patients demonstrated safety and feasibility with minor issues. Adverse events included one serious adverse event possibly related to investigational medicinal product and two moderate-related adverse events. More than 50% of the patients with advanced and mainly nonimmunogenic tumors showed clinical benefits, including partial responses, stable diseases, and prolonged survival. In recurrent/metastatic head and neck squamous cell carcinoma, one patient achieved a partial response, whereas another survived for more than 7 years without anticancer therapy for over 5 years. MVX-ONCO-1 is safe, well tolerated, and beneficial across several tumor types. Ongoing phase IIa trials target patients with advanced recurrent/metastatic head and neck squamous cell carcinoma after initial systemic therapy. Significance: This first-in-human phase I study introduces a groundbreaking approach to personalized cancer immunotherapy, addressing limitations of traditional strategies. By combining autologous irradiated tumor cells as a source of patient-specific antigens and utilizing encapsulated cell technology for localized, sustained delivery of granulocyte–macrophage colony-stimulating factor as an adjuvant, the study shows a very good safety and feasibility profile. This innovative approach holds the promise of addressing tumor heterogeneity by taking advantage of each patient's antigenic repertoire.

1 May 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
EFEugenio Fernandez
Eugenio Fernandez
WCWulfran Cacheux
Wulfran Cacheux
JFJean-Louis Frossard
Jean-Louis Frossard
TKThibaud Koessler
Thibaud Koessler
MAMagali Abou
Magali Abou
ARArnaud Roth
Arnaud Roth

1 November 2016 in JAAD Case Reports
Verified
Journal Article
Open access
RMRastine Merat
Rastine Merat
OSOlivia Seyde
Olivia Seyde
EFEugenio Fernandez
Eugenio Fernandez
GKGürkan Kaya
Gürkan Kaya